Literature DB >> 10319240

Intermittent claudication in older patients. Practical treatment guidelines.

H Boccalon1.   

Abstract

The prevalence of intermittent claudication (IC) increases with age; when questioned, older patients consider increased difficulty in walking to be a normal consequence of aging. Although the prognosis for the involved limb with IC is relatively good, IC is an important clinical predictor of increased cardiovascular mortality. It is important to effect a minimal strategy for determining the presence of lesions in different vascular regions: carotids, coronaries, aorta and renal arteries. The goals for the treatment of IC in the elderly are to improve the walking distance and quality of life and to increase survival. Practical guidelines for the treatment of IC are to first establish a correct diagnosis. Then, patients have to apply life-style modifications and participate in an exercise programme, with the next treatment step involving the use of antiplatelet drugs. However, it must be remembered that older patients could have limitations on exercise; in such cases, a vasoactive drug should be considered. The third guideline consists of multifocal evaluation of the arteries, specifically the coronaries, carotids and abdominal aorta. The existence of an iliac obstruction or stenosis requires consideration of the 2 last guidelines. In more than 75% of cases, elderly patients have femoropopliteal or distal arterial obstructions: exercise and a vasoactive drug should be employed in these instances. The presence of iliac lesions has to be discussed in the presence of a multidisciplinary team in a vascular centre, and should consider the usefulness of percutaneous transluminal angioplasty or surgery.

Entities:  

Mesh:

Year:  1999        PMID: 10319240     DOI: 10.2165/00002512-199914040-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  44 in total

1.  The effect of naftidrofuryl on intermittent claudication: a meta-analysis.

Authors:  P Lehert; F E Riphagen; S Gamand
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

2.  The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease.

Authors:  S R Tunis; E B Bass; E P Steinberg
Journal:  N Engl J Med       Date:  1991-08-22       Impact factor: 91.245

Review 3.  Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.

Authors:  L B Barradell; R N Brogden
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 4.  Evaluation and management of patients with both peripheral vascular and coronary artery disease.

Authors:  B J Gersh; C S Rihal; T W Rooke; D J Ballard
Journal:  J Am Coll Cardiol       Date:  1991-07       Impact factor: 24.094

5.  Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985.

Authors:  H A Cameron; P C Waller; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

6.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

7.  Influence of screening on the incidence of ruptured abdominal aortic aneurysm: 5-year results of a randomized controlled study.

Authors:  R A Scott; N M Wilson; H A Ashton; D N Kay
Journal:  Br J Surg       Date:  1995-08       Impact factor: 6.939

8.  Exercise training improves functional status in patients with peripheral arterial disease.

Authors:  J G Regensteiner; J F Steiner; W R Hiatt
Journal:  J Vasc Surg       Date:  1996-01       Impact factor: 4.268

9.  Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS).

Authors:  D Bergqvist; B Almgren; J P Dickinson
Journal:  Eur J Vasc Endovasc Surg       Date:  1995-07       Impact factor: 7.069

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  3 in total

Review 1.  Naftidrofuryl: a review of its use in the treatment of intermittent claudication.

Authors:  David R Goldsmith; Keri Wellington
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  Intermittent claudication: pharmacoeconomic and quality-of-life aspects of treatment.

Authors:  Gregorio Brevetti; Roberta Annecchini; Roxanna Bucur
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

3.  Association of Age with Mortality Rate after Femoropopliteal Endovascular Therapy for Intermittent Claudication.

Authors:  Mitsuyoshi Takahara; Yoshimitsu Soga; Masahiko Fujihara; Daizo Kawasaki; Amane Kozuki; Osamu Iida
Journal:  J Atheroscler Thromb       Date:  2021-02-27       Impact factor: 4.394

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.